miRecule

Executive Summary

miRecule is a privately held biotechnology company founded in 2024 and headquartered in Gaithersburg, Maryland. The company specializes in developing RNA-based therapeutics for cancer and muscular dystrophy, leveraging genomic patient data to design highly personalized treatments. By integrating insights from patient genetics, miRecule aims to create therapies that address the root causes of these debilitating diseases, potentially improving efficacy and reducing side effects compared to conventional approaches. The company's platform is still in early stages, but its focus on RNA therapeutics—a rapidly advancing field—positions it to capitalize on growing interest in gene-targeted modalities.

Upcoming Catalysts (preview)

• Q1 2027IND Filing for Lead Indication (Cancer)60% success
• Q3 2026Preclinical Proof-of-Concept Data in Muscular Dystrophy70% success
• Q4 2026Strategic Partnership or Funding Round50% success